77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

77 Association between programmed death-ligand 1 (PD-L1) expression and gene signatures of response or resistance to tislelizumab monotherapy in hepatocellular carcinoma (HCC)

Bibliographic Details
Main Authors:	Yun Zhang, Xin Li, Hongming Pan, Yoon-Koo Kang, Chia-Jui Yen, Ming-Mo Hou, Kun-Ming Rau, Ying Yuan, Xiaopeng Ma, Xikun Wu, Jong-Seok Lee, Cunjing Yu, Katie Wood
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma
by: Yun Zhang, et al.
Published: (2020-11-01)

Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
by: Bhumsuk Keam, et al.
Published: (2020-06-01)

79 Tumor-immune signatures associated with response or resistance to tislelizumab (Anti-PD-1) in esophageal squamous cell carcinoma (ESCC)
by: Wei Huang, et al.
Published: (2020-11-01)

Tislelizumab uniquely binds to the CC′ loop of PD‐1 with slow‐dissociated rate and complete PD‐L1 blockage
by: Yuan Hong, et al.
Published: (2021-03-01)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
by: Bin Zhao, et al.
Published: (2020-07-01)

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
by: Hongming Pan, et al.
Published: (2020-06-01)

Limited Impact of Anti-PD-1/PD-L1 Monotherapy for Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2020-10-01)

Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence
by: Yihang Qi, et al.
Published: (2021-06-01)

76 Potential mechanisms of resistance identified through analysis of multiple biomarkers in immune hot non-responders with non-small cell lung cancer (NSCLC) treated with tislelizumab
by: Yun Zhang, et al.
Published: (2020-11-01)

Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study
by: Yu-Pei Chen, et al.
Published: (2020-07-01)

Pathologic complete response after neoadjuvant tislelizumab and chemotherapy for Pancoast tumor: A case report
by: Wen‐Fang Tang, et al.
Published: (2021-04-01)

Efficacy of Anti-PD-1/PD-L1 Monotherapy or Combinational Therapy in Patients Aged 75 Years or Older: A Study-Level Meta-Analysis
by: Run-Cong Nie, et al.
Published: (2021-03-01)

Case Report: Successful Management of a Refractory Plasmablastic Lymphoma Patient With Tislelizumab and Lenalidomide
by: Lili Cheng, et al.
Published: (2021-07-01)

Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer
by: Marta Zayas-Soriano, et al.
Published: (2021-01-01)

PD-1 Antibody Monotherapy for Malignant Melanoma: A Systematic Review and Meta-Analysis.
by: Zhijuan Lin, et al.
Published: (2016-01-01)

Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients
by: Xuqi Sun, et al.
Published: (2021-07-01)

Systemic Sequential Therapy of CisGem, Tislelizumab, and Lenvatinib for Advanced Intrahepatic Cholangiocarcinoma Conversion Therapy
by: Yuan Ding, et al.
Published: (2021-08-01)

Prognostic role of PD-L1 for HCC patients after potentially curative resection: a meta-analysis
by: Gao-Min Liu, et al.
Published: (2019-01-01)

Identification of 15 lncRNAs Signature for Predicting Survival Benefit of Advanced Melanoma Patients Treated with Anti-PD-1 Monotherapy
by: Jian-Guo Zhou, et al.
Published: (2021-04-01)

Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort
by: Pedro Barata, et al.
Published: (2020-10-01)

Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review
by: Tian Shen MD, et al.
Published: (2020-12-01)

228 Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy
by: Xiaoling Yang, et al.
Published: (2020-11-01)

Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy
by: Valerie Glutsch, et al.
Published: (2019-07-01)

PD-1 Immune Checkpoint Inhibitor Therapy Malignant Tumor Based on Monotherapy and Combined Treatment Research
by: Yu Zhang, et al.
Published: (2021-03-01)

PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC
by: Xiao Wang, et al.
Published: (2020-11-01)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
by: Deirdre Kelly, et al.
Published: (2021-01-01)

Correlation of Clinical Parameters with Intracranial Outcome in Non-Small Cell Lung Cancer Patients with Brain Metastases Treated with Pd-1/Pd-L1 Inhibitors as Monotherapy
by: Konstantinos Rounis, et al.
Published: (2021-03-01)

Case Report: Transarterial Chemoembolization in Combination With Tislelizumab Downstages Unresectable Hepatocellular Carcinoma Followed by Radical Salvage Resection
by: Jiashuo Chao, et al.
Published: (2021-03-01)

Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient
by: Minjiang Chen, et al.
Published: (2021-05-01)

Efficacy of combined hypo-fractionated radiotherapy and anti-PD-1 monotherapy in difficult-to-treat advanced melanoma patients
by: Anissa Roger, et al.
Published: (2018-07-01)

Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
by: Matsubara T, et al.
Published: (2021-03-01)

The association of HMGB1 gene with the prognosis of HCC.
by: Jianbiao Xiao, et al.
Published: (2014-01-01)

Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis
by: Yuhan Wei, et al.
Published: (2020-01-01)

Corrigendum: PKM2-Induced the Phosphorylation of Histone H3 Contributes to EGF-Mediated PD-L1 Transcription in HCC
by: Xiao Wang, et al.
Published: (2021-07-01)

Germline Variation in <i>PDCD1</i> Is Associated with Overall Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Monotherapy
by: Mirjam de With, et al.
Published: (2021-03-01)

Rationale and design of a prospective, multicenter, phase II clinical trial of safety and efficacy evaluation of long course neoadjuvant chemoradiotherapy plus tislelizumab followed by total mesorectal excision for locally advanced rectal cancer (NCRT-PD1-LARC trial)
by: An, Y., et al.
Published: (2022)

PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
by: Margarita Majem, et al.
Published: (2021-03-01)

Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.
by: Magdalena Zajac, et al.
Published: (2020-01-01)

282 Pan-tumor analysis of the association between PD-L1 combined positive score and response to pembrolizumab monotherapy
by: Jared Lunceford, et al.
Published: (2020-11-01)

A Partial Response of Pulmonary Pleomorphic Carcinoma to Camrelizumab (PD1 Monoclonal Antibody) Monotherapy: A Case Report
by: Chen Y, et al.
Published: (2020-12-01)